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ArdA antirestriction proteins are encoded by genes present in many conju-
gative plasmids and transposons within bacterial genomes. Antirestriction
is the ability to prevent cleavage of foreign incoming DNA by restriction-
modification (RM) systems. Antimodification, the ability to inhibit modifi-
cation by the RM system, can also be observed with some antirestriction
proteins. As these mobile genetic elements can transfer antibiotic resistance
genes, the ArdA proteins assist their spread. The consequence of antire-
striction is therefore the enhanced dissemination of mobile genetic ele-
ments. ArdA proteins cause antirestriction by mimicking the DNA
structure bound by Type I RM enzymes. The crystal structure of ArdA
showed it to be a dimeric protein with a highly elongated curved cylindrical
shape [McMahon SA et al. (2009) Nucleic Acids Res 37, 4887–4897]. Each
monomer has three domains covered with negatively charged side chains
and a very small interface with the other monomer. We investigated the
role of the domain forming the dimer interface for ArdA activity via site-
directed mutagenesis. The antirestriction activity of ArdA was maintained
when up to seven mutations per monomer were made or the interface was
disrupted such that the protein could only exist as a monomer. The anti-
modification activity of ArdA was lost upon mutation of this domain. The
ability of the monomeric form of ArdA to function in antirestriction sug-
gests, first, that it can bind independently to the restriction subunit or the
modification subunits of the RM enzyme, and second, that the many ArdA
homologues with long amino acid extensions, present in sequence databases,
may be active in antirestriction.
Structured digital abstract
 ArdA and ArdA bind by molecular sieving (1, 2)
 ArdA and ArdA bind by cosedimentation in solution (1, 2)
Abbreviations
2-ME, 2-mercaptoethanol; anti-RM, antirestriction and antimodification; AUC, analytical ultracentrifugation; f/fo, frictional ratio; HGT,
horizontal gene transfer; HsdM, methyltransferase subunit; HsdR, restriction subunit; HsdS, DNA sequence specificity subunit.
MTase, methyltransferase; RM, restriction-modification; SEC, size exclusion chromatography; TCEP, tris(2-carboxyethyl)phosphine.
TRD, target recognition domain; WT, wild-type.
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Introduction
The majority of eubacteria contain the genes for active
or putative DNA restriction-modification (RM) sys-
tems [1–3]. It is clear that their function is to protect
the host cell from invasion by foreign DNA by recog-
nising specific DNA sequences and triggering an endo-
nuclease activity that rapidly cleaves the foreign DNA.
The host DNA sequences are maintained in a methy-
lated state by the modification methytransferase
(MTase) function.
Despite the demonstrated efficacy of the RM sys-
tems, genome analysis of pathogenic bacteria from
both clinical and environmental settings makes it
abundantly clear that horizontal gene transfer (HGT)
by transformation, transduction or conjugation is com-
mon within species and even between species. HGT is
directly responsible for the spread of antibiotic resis-
tance genes [4]. In fact, the spread of antibiotic resis-
tance and the resultant selective pressure caused by the
continual use of antibiotics is a serious and almost
unstoppable phenomenon [5–8]. It is therefore impor-
tant for understanding and tackling antibiotic resis-
tance to ascertain the mechanism by which HGT
circumvents such an apparently effective RM defence.
The identification of potential antirestriction and anti-
modification (anti-RM) genes within the mobile ele-
ments [9,10] suggests a mechanism by which the
mobile elements can overcome the RM systems. These
anti-RM systems have occasionally been acquired and
maintained by the host organism, and the occasional
activation of such genes weakens or negates the RM
defence system, allowing further HGT [11,12].
The first plasmid-borne antirestriction system identi-
fied was encoded by the ardA locus of the ColIbP-9
enterobacterial plasmids [13]. Conserved ardA genes
have subsequently been identified in representatives of
other plasmid incompatibility groups [10,13–16], other
bacterial genomes [17], and ORF18 of the Tn916 con-
jugative transposon from Streptococcus faecalis [17].
The structure of ORF18 ArdA from Tn916 reveals a
highly elongated dimeric protein with a surface deco-
rated with negative charges in such a way that it mim-
ics the shape and charge distribution of ~ 42 bp of
DNA [18]. Thus, ArdA is a DNA mimic anti-RM pro-
tein similar to the Ocr DNA mimic anti-RM protein
encoded by bacteriophage T7 [19,20], although their
secondary structures are very different. ArdA mono-
mers are further divided into three small domains com-
posed of amino acids 1–61, 62–103, and 104–165, with
the third domain in each monomer forming the dimer
interface. The negative charges on the surface of ArdA
are spread over all three domains. ORF18 ArdA
appears to be able to dissociate into monomers at low
concentrations in buffer solution [17], raising the possi-
bility that the monomer form may be active in addi-
tion to the dimer form. It may even be the case that
one form targets the modification activity and the
other form targets the restriction activity of the RM
system, as some ArdA proteins show differential
effects on restriction and modification, depending on
the level of expression in vivo [16,21–25].
The Type I RM systems are the targets for ArdA,
and are widespread in nature [26]. Moreover, Type I
RM systems play a clear role in HGT, as exemplified
by the fact that they are used to define clinical strains
of Staphylococcus aureus [5,27]. Type I RM enzymes
[2] are complex hetero-oligomers of two restriction
subunits (HsdRs), two methyltransferase subunits
(HsdMs), and one DNA sequence specificity subunit
(HsdS) (total molecular mass of ~ 440 kDa). Depend-
ing on the methylation status of the DNA substrate,
this complex functions as either a restriction endonu-
clease or an MTase. These enzymes recognise an asym-
metric, bipartite sequence (for example, EcoKI
recognises AACNNNNNNGTGC), and require ATP
to affect cleavage at a distant site reached via extensive
DNA translocation. Two HsdMs and one HsdS form
an active MTase in the absence of HsdR [28,29]. Many
genomes contain multiple Type I RM systems [3], and
some have the ability to switch between multiple DNA
specificities [30]. Type I RM systems are extensively
represented within clinical strain collections such as
the Escherichia coli ECOR collection [26], and can be
grouped into families, defined by subunit complemen-
tation for example, in which HsdR and HsdM are
highly conserved [31,32]. HsdS sequences show
extreme variability in two ~ 150-residue regions. These
regions are called target recognition domains (TRDs).
The N-terminal TRD recognises the first part of the
bipartite sequence, and the C-terminal TRD recognises
the second part. TRDs can be swapped within a family
to generate predictable changes in the enzyme specific-
ity.
In this study, we investigated the effect of mutagene-
sis in domain 3 of ORF18 ArdA, which forms the
dimer interface and is predicted to interact with the
MTase core of a Type I RM enzyme [18]. We
observed that some of the mutations created solely
monomeric forms of ArdA, whereas others either had no
effect on protein structure or could not be stably
expressed. The purified ArdA proteins, whether mono-
meric or dimeric, showed reduced antimodification
activity against EcoKI, but most retained normal
4904 FEBS Journal 280 (2013) 4903–4914 ª 2013 The Authors. FEBS Journal published by John Wiley & Sons Ltd on behalf of FEBS
Quaternary structure of ArdA G. A. Roberts et al.
antirestriction activity. These data indicate that antire-
striction activity resides in domains 1 and 2 of ArdA,
and that antimodification activity resides in domain 3.
Results
Location of amino acid substitutions on the
dimer of ORF18 ArdA
The negatively charged amino acids selected for muta-
genesis are shown in Table 1, and were created by the
mutagenesis primers Table S1, with plasmid pORF18wt
(Fig. S1) as a template. In addition, two leucines
(Leu127 or Leu134) at the dimer interface in the crys-
tal structure were individually mutated to glutamate,
with the idea that the introduction of a negative
charge would prevent formation of the hydrophobic
dimer interface. The model of ArdA bound to the
EcoKI MTase suggests that these amino acid substitu-
tions occur at positions equivalent to the region of
DNA recognised by the S subunit of the RM enzyme
(Fig. 1). The physical effects of these mutations on the
protein structure were first analysed in vitro, to deter-
mine whether the substitutions had disrupted the inter-
face to form the desired monomeric forms of ArdA or
led to other structural changes. Subsequently, in vivo
activity tests were performed to determine whether
anti-RM activity was affected.
Characterization of ArdA mutant proteins in vitro
Overexpression of the mutant proteins by using
mutated forms of plasmid pORF18wt (Fig. S2) was
only observed for the Mut5, Mut6 and L127E ArdA
proteins, as well as wild-type (WT) ArdA. The other
mutant proteins, Mut5/6 and L134E, could not be
observed in cell extracts, and nor were either of these
proteins observed after fractionation of the cell
extracts via ion exchange chromatography (no band of
an appropriate size was visible on an SDS/PAGE gel;
data not shown). Thus, in vitro characterization was
confined to Mut5, Mut6 or L127E ArdA. Cells har-
bouring the various constructs were grown and har-
vested, and the recombinant proteins were purified to
near homogeneity as described previously for WT
ORF18 ArdA [17]. Figure S2a shows the protein frac-
tions eluting from the anion exchange (DEAE) column
prior to further purification by preparative size exclu-
sion chromatography (SEC).
The folding and unfolding curves measured by tryp-
tophan fluorescence were essentially identical for WT
ORF18 ArdA [17], and Mut5, Mut6, and L127E ArdA
(Fig. S2b). The midpoints of the unfolding transitions
were 2.20  0.14 M guanidine hydrochloride [24],
2.39  0.46 M guanidine hydrochloride, 2.44  0.08 M
guanidine hydrochloride, and 2.13  0.13 M guanidine
hydrochloride, respectively. The free energies of
stabilization were 20.0  3.3 kJmol1 [17], 15.4 
3.4 kJmol1, 21.1  4.7 kJmol1, and 20.8  4.1
kJmol1 respectively. The transition slopes divided by
RT (ideal gas constant multiplied by temperature) were
1.97  0.33, 1.90  0.47, 3.67  0.77, and 2.03 
0.42, respectively. The transition slopes are related to
the change in exposed surface area as the protein
unfolds. This similarity in stability was expected, as
the tryptophans are not located near to the dimer
interface, and would only be sensitive to changes in
tertiary structure rather than in quaternary structure.
CD spectroscopy was used to establish the secondary
structure content of all of the purified proteins, and
LC-MS was used to determine the exact molecular
mass of the Mut5 and Mut6 monomers (Figs S3 and
S4). These data suggest that the polypeptide fold was
not greatly compromised by the amino acid substitu-
tions.
Analytical SEC of ArdA
It has previously been observed that the apparent
molecular mass of WT ORF18 ArdA changes as its
concentration changes [17]. At high concentration, WT
ORF18 ArdA eluted from a SEC column at an appar-
ent molecular mass of > 100 kDa, and at low concen-
tration it eluted with an apparent molecular mass of
~ 40 kDa (Figs 2 and S5). As the crystal structure [18]
showed a dimeric protein, it was assumed that the pro-
tein was a dimer of mass 38 kDa at high concentration
and a monomer of mass 19 kDa at low concentration,
despite the fact that the SEC gave apparent molecular
masses far different from these expected values. The
Table 1. Amino acid substitutions created in domain 3 of WT
ORF18 ArdA.
Mutant
name
Amino acid
changes
Total number
of mutated
residues
Mut5 D109N, D111N,
D112N, D115N
4
Mut6 E122Q, E123Q,
E129Q
3
Mut5/6 D109N, D111N,
D112N, D115N,
E122Q, E123Q,
E129Q
7
L127E L127E 1
L134E L134E 1
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discrepancy between observed and expected molecular
mass was attributed to the highly elongated shape of
the protein, which would give it an unusually large
hydrodynamic radius. With this assumption, the data
were previously modelled as a monomer–dimer equilib-
rium with a dissociation constant of 1.3  0.3 lM [17],
although this calculation used the concentration of the
injected sample rather than the concentration on the
column, which will be lower because of dilution during
the chromatography.
Mut5, Mut6 and L127E ArdA were also analysed
by SEC. Figure 2 (and Figs S5c and S5e) shows that
Mut5 and L127E ArdA eluted with an apparent
molecular mass of ~ 40 kDa at all concentrations
below 100 lM. Above 100 lm, the apparent molecular
mass of L127E ArdA started to increase. The concen-
trations of the proteins are the concentrations of the
injected 40-L samples, and the actual concentration of
the samples as they move through the column will be
somewhat smaller, owing to sample dilution. If the
monomer–dimer equilibrium model for ArdA is cor-
rect, then it would appear that Mut5 and L127E ArdA
are monomers at most concentrations. Mut6 ArdA
behaved in the same manner as WT ORF18 ArdA,
showing a decrease in apparent molecular mass as con-
centration decreased (Figs 2 and S5d).
In order to investigate the discrepancy between the
observed and expected molecular masses, an absolute
measure of molecular mass was sought for WT
ORF18 ArdA and L127E ArdA, by the use of analyti-
cal ultracentrifugation (AUC). Such measurements
would serve to explain the anomalous molecular
masses observed with SEC.
Sedimentation equilibrium AUC of ArdA
Sedimentation equilibrium measurements can give an
absolute value for molecular mass. Three different
A
B
C
Fig. 1. Structural models of the S subunit (yellow ribbon) of EcoKI
bound to WT ORF18 ArdA (Protein Data Bank: 2W82) and the DNA
target sequence. (A) ArdA chains are shown as grey and white
ribbons, with Mut5 and Mut6 regions shown in green and magenta
respectively. Sites of amino acid substitution within these regions
are shown in a ball and stick representation in green (Mut5),
magenta (Mut6), and grey (L127E), respectively. Leu134 is shown
in black ball and stick form. (B) An expanded view of the ArdA
dimer interface coloured as in (A). (C) The DNA bases are coloured
in purple for sequence outside the DNA target sequence, green for
the defined bases in the target sequence, and orange for the
central undefined bases in the target sequence.
140
120
100
80
60
40A
pp
ar
en
t m
ol
ec
ul
ar
 m
as
s 
(k
D
a)
20
1
Concentration (µM)
10 100
Fig. 2. SEC analysis to investigate the solution apparent molecular
mass as a function of protein monomer concentration injected onto
the column. ●, WT ORF18 ArdA; ○, L127E ArdA; □, Mut5 ArdA;
■, Mut6 ArdA.
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sample concentrations of WT ArdA or L127E ArdA
were analysed individually, to give an idea of their
behaviour in solution (Fig. 3A,B). Initially, all samples
were modelled as single species (Table 2). The whole
cell weight average molecular mass of WT ORF18
ArdA was not observed to change over the concentra-
tion range studied (0.6–15 lM), and had an average of
37.4 kDa, indicating that WT ORF18 ArdA exists as
a dimer (Fig. 3A). The detection limits on the AUC
instrument precluded measurements of the dissociation
of WT ORF18 ArdA at very low concentrations. A
global analysis for WT ORF18 ArdA was also per-
formed, assuming the same molecular mass at all three
concentrations, to confirm that a single average molec-
ular mass was appropriate. Individual analyses for
L127E ArdA showed that the molecular mass changed
A
C
B
3.0
2.5
2.0
1.5c 
(s
)
1.0
0.5
0.0
0
Sedimentation Coefficient (Svedbergs)
2 4 6 8 10 12 14
17 000 r.p.m.
27 000 r.p.m.
35 000 r.p.m.
17 000 r.p.m.
27 000 r.p.m.
35 000 r.p.m.
17 000 r.p.m.
27 000 r.p.m.
35 000 r.p.m.
17 000 r.p.m.
27 000 r.p.m.
35 000 r.p.m.
Fig. 3. AUC of WT ORF18 ArdA and L127E ArdA. (A) SEDPHAT sedimentation equilibrium data analysis of WT ORF18 ArdA at 15 lM at
17 000 r.p.m., 27 000 r.p.m., and 35 000 r.p.m. , with detection at 280 nm. The samples had reached equilibrium at each rotor speed, as
the rmsd between scans was below  0.01 absorbance units (typical noise level in the centrifuge). The fitted line and residuals are for a
single-species fit. (B) SEDPHAT sedimentation equilibrium data analysis of L127E ArdA at 15 lM at 17 000 r.p.m., 27 000 r.p.m., and
35 000 r.p.m., with detection at 280 nm. The samples had reached equilibrium at each rotor speed, as the rmsd between scans was below
 0.01 absorbance units (typical noise level in the centrifuge). The fitted lines and residuals are for a two-species fit. (C) SEDFIT
sedimentation velocity c(s) distributions of WT ORF18 ArdA (dashed line) and L127E ArdA (solid line) show that the proteins have different
sedimentation velocity properties in solution.
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with respect to concentration and that the global anal-
ysis was inappropriate (Table 2). At low concentra-
tions, the molecular mass was between 21.2 and
17.0 kDa, indicating that it is a monomer in solution
at these concentrations (Table 2). However, L127E
ArdA at 15 lM was modelled as two species, and the
fit was improved (Table 2; Fig. 3B). The two species
in this fit had molecular masses of 39.1 and 20.3 kDa,
suggesting that, at 15 lM, L127E ArdA is in rapid
exchange between monomeric and dimeric forms. The
presence of monomers and dimers at high concentra-
tion is consistent with the increase in the apparent
molecular mass for L127E ArdA observed in the SEC
experiment at high concentrations (Fig. 2). The 15 lM
data were also modelled as a monomer–dimer equilib-
rium with SEDPHAT [33], fixing the monomer molecular
mass of 19.1 kDa. This gave a dissociation constant of
10 lM, but carried a high rmsd of 0.01 (a good fit has
0.001) and largely reduced v2 value of 7.9 (a good fit
has a value of 1), suggesting a poorer fit than the two-
species fit, which had a v2 of 1.95.
The discrepancy in the concentration range between
the SEC and the AUC experiments in which the two
proteins show monomeric–dimeric behaviour can be
explained by the fact that the SEC column dilutes the
protein by approximately five-fold to 10-fold but we
have reported the injected SEC protein concentration
and calculated the apparent dissociation constant for
the proteins by using the injected concentration. As
the SEC detection was performed with tryptophan flu-
orescence emission, there is no reliable method to
determine the dilution factor.
Sedimentation velocity AUC of ORF18 ArdA and
L127E ArdA
The samples for sedimentation velocity AUC had con-
centrations of 33.9 lM and 36.9 lM, so WT ORF18
ArdA should be primarily in the large molecular mass
form and L127E ArdA in both the monomeric and
dimeric forms, as judged from the SEC data shown in
Fig. 2 and the sedimentation equilibrium results.
Absorbance scans before and after a low-speed centri-
fugation step were identical, indicating the absence of
high molecular mass aggregates. Preliminary absor-
bance scans of the samples indicated that the absor-
bance at 280 nm would be outside of the linear range
of the detector, but that 260 nm would give an accept-
able signal.
Analysis of the radial absorbance scans (Fig. S6)
used continuous c(s) distribution analysis to show the
distribution of sedimentation coefficients in the sam-
ples (Fig. 3C). For the major species present in each
sample, calculated molecular masses and proportions
are summarized in Table 3. The major species (89%)
for WT ORF18 ArdA had a sedimentation coefficient,
so20,w, of 2.6 S, and the major species (78%) for
L127E ArdA had an so20,w of 2.3 S. Other minor spe-
cies contributed to the remaining signal, particularly
for L127E ArdA. These small amounts of material
had s-values between 15 S and 50 S in the c(s) analysis
(data not shown). L127E ArdA showed a lower sedi-
mentation coefficient than WT ORF18 ArdA and a
slightly broadened peak. The lower sedimentation
coefficient could be attributable to increased asymme-
try, unfolded protein conformations, a change in pro-
tein hydration, or a different multimeric state. The
broadened peak could arise from equilibrium between
a monomeric L127E ArdA and a dimeric form.
Assuming that a different multimeric state is the
source of the difference in sedimentation coefficient
between WT ORF18 ArdA and L127E ArdA, SEDFIT
[34] designated apparent molecular masses for the two
species as 32.6 kDa for WT ORF18 ArdA and
15.1 kDa for L127E ArdA. The f/fo determined from
data analysis was also examined.
The frictional ratio (f/fo) is given in Table 3. This is
a parameter describing the asymmetry of the molecules
sedimenting in solution. A spherical unhydrated mole-
cule will have an f/fo of 1.0, whereas values in the
Table 2. Sedimentation equilibrium analytical ultracentrifugation analysis for determination of molecular mass (m) in kDa. Rmsd and reduced
v2 are given.
Sample
15.0 lM 3.0 lM 0.6 lM
Global analysis of all
concentrations
m rmsd v2 m rmsd v2 m rmsd v2 m rmsd v2
WT ORF18 ArdA 39.4 0.010 4.34 36.2 0.014 7.35 38.3 0.014 8.19 37.4 0.010 6.36
L127E ArdA 27.3a 0.007 2.12 21.2 0.005 1.03 17.0 0.005 1.15 26.7 0.010 2.37
a The value given is for analysis assuming a single species. However, at the highest concentration, the data fitted best to two species in
solution with molecular masses of 39.1 and 20.3 kDa (rmsd = 0.007, v2 = 1.95). Global simultaneous analysis of all three concentrations
assuming a single species was performed with SEDPHAT.
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range 1.1–1.3 are expected for hydrated, globular pro-
teins [35]. This f/fo analysis suggests that WT ORF18
ArdA with an f/fo of 1.50 is very asymmetric, as would
be expected from the crystal structure. Assuming a
hydration level of ~ 30% for the proteins, the experi-
mental f/fo for WT ORF18 ArdA gives an axial ratio
of ~ 7 if modelled as a prolate ellipsoid [35].
The data indicate that L127E ORF18 ArdA has an
f/fo of 1.08 (Table 3), which would correspond to an
almost globular protein if there were only a single spe-
cies present in solution. The crystal structure of ArdA
indicates that a monomer of ArdA should have an
axial ratio of ~ 3.5 if modelled as a prolate ellipsoid,
and an f/fo of ~ 1.25. The observed f/fo for L127E
ArdA was lower than expected, but this can be
explained by the measurement of sedimentation veloc-
ity being skewed by the presence of more than one
species, namely the monomer–dimer equilibrium indi-
cated by SEC and sedimentation equilibrium.
Furthermore, calculation of sedimentation velocity
and f/fo by HYDROPRO and SOMO [36–38] from bead
models calculated with the crystal monomer and dimer
showed good agreement with the experimental data
for WT ORF18 ArdA, and, because of the monomer–
dimer equilibrium, only qualitative agreement for the
mutant (Table 4).
Comparison of in vivo activity of ORF18 ArdA
and ArdA mutants against the EcoKI Type I RM
system
After determination of the effects of the amino acid
substitutions on the quaternary structure of ArdA, the
ability of the mutant ArdA proteins to inhibit restric-
tion and modification by the EcoKI RM system
in vivo was examined. The in vivo activities of WT
ORF18 ArdA and the mutant ArdA proteins were
examined with a restriction assay in which the ability
of phage kv.0 to infect two strains of E. coli, one with
the EcoKI RM system, E. coli NM1049(DE3), and
one without the RM system, E. coli NM1261(DE3),
transformed with the expression plasmids, was investi-
gated (Table 5). The control experiment with the
pTRC99 vector [39] showed that E. coli NM1261
(DE3) was easily infected by phage kv.0 (high titre),
but that E. coli NM1049(DE3) was not easily infected
(low titre), owing to restriction by the EcoKI RM
system.
Cells transformed with plasmid expressing WT
ORF18 ArdA or active ArdA mutants (Mut6 and
L127E) showed a high titre of phage for both bacterial
strains, indicating that the ArdA proteins were abol-
ishing the restriction activity of EcoKI and were
~ 80% as effective as WT ORF18 ArdA. Cells trans-
formed with plasmids expressing Mut5 were only 5%
as active as WT ArdA; L134E ArdA showed 2%
activity, and Mut5/6 ArdA showed essentially zero
(0.3%) inhibition of restriction by the EcoKI system.
The low antirestriction activity of Mut5/6 and L134E
ArdA is most probably a consequence of their poor
expression, whereas the low activity of Mut5 ArdA,
which was expressed well, is suggestive of a defect in
activity.
A further in vivo test was performed to determine
whether some of the mutant ArdA proteins were able
to prevent modification of phage kv.0 by EcoKI.
Table 4. Comparison of experimental sedimentation velocity and f/fo for the major sedimenting species, with values calculated with SOMO
[37,38] and HYDROPRO [36], based on the crystal structure of the ArdA dimer for WT ORF18 ArdA [18] and the monomer coordinates
extracted from the crystal structure for L127E ArdA.
Protein
Sedimentation velocity SOMO HYDROPRO
so20,w f/fo s
o
20,w f/fo s
o
20,w f/fo
WT ORF18 ArdA 2.6 1.50 2.64 1.55 2.40 1.63
L127E ArdA 2.3 1.08 1.92 1.35 1.72 1.43
Table 3. Estimated molecular mass distributions and f/fo values from sedimentation velocity AUC. Rmsd values of sedimentation coefficient
(so20,w) and f/fo are given for the major sedimenting species. The rmsd at a confidence level of 0.683 (one standard deviation) is given for
the major sedimenting species.
Sample Concentration (lM)
Measured sedimentation coefficient (so20,w)
(% composition) of 260-nm signal Total% rmsd f/fo
WT ORF18 ArdA 33.9 2.6 (89.0) 5.2 (4.3) 9.0 (3.0) 96.3 0.0076 1.50
L127E ArdA 36.9 0–0.25 (6.3) 0.25–0.75 (2.6) 2.3 (77.7) 86.6 0.0100 1.08
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Phage were recovered after growth on E. coli NM1049
(DE3) transformed with the plasmid expressing WT
ORF18 ArdA or with plasmid expressing Mut5, Mut6,
L127E or L134E ArdA, and tested for modification by
comparing the titre of the recovered phage on
E. coli NM1049(DE3) and E. coli NM1261(DE3)
(Table 5). An antimodification value of 122 was
obtained for phage recovered from the strain trans-
formed with the WT ORF18 ArdA plasmid, indicating
that a proportion of the recovered phages were
unmodified and that ORF18 ArdA was partially active
as an antimodification protein, as expected. However
an efficiency of plating of order 1 was obtained for
phage recovered from the strains expressing the ArdA
mutants or containing the plasmid vector. This indi-
cated that these mutant proteins were not able to pre-
vent the methylation reaction of EcoKI in vivo, and
that the phage DNA had been modified. Whereas this
loss of antimodification activity can be attributed to
low protein expression for Mut5/6 and L134E ArdA,
the other proteins were expressed well, so the loss of
antimodification activity indicates a loss of interaction
between the ArdA mutant and the EcoKI enzyme.
Discussion
Our results show that mutations in domain 3 of
ORF18 ArdA affect the ability of the protein to form
the dimer observed in the crystal structure. Examina-
tion of the structural model of the ArdA dimer bound
to HsdS of the EcoKI MTase (Fig. 1A,B) [18] and the
model of DNA bound to HsdS (Fig. 1C) reveals that
the locations of the mutations analysed in this study
are located near the DNA-binding site of the TRDs in
HsdS (Mut5 and Mut6) or at the ArdA dimer inter-
face (L127E and L134E). The observation that Mut5
ArdA is a monomer when the substitutions made are
not at the interface suggests that they have caused a
minor alteration in protein structure, which manages
to propagate through the structure to the dimer
interface, preventing its correct formation. Of note is
the change D112N at the start of an a-helix. Removal
of the charge at this end of the helix and consequent
interference with the normal electrostatic dipole of
the helix may alter its orientation, even though no
affect on folding stability or secondary structure was
observed. The substitutions forming Mut6 ArdA
commence at the other end of this same a-helix, but
do not disrupt dimerization. As most of the substitu-
tions in Mut6 ArdA are on a loop in the structure,
perhaps there is sufficient flexibility in the loop to
accommodate them but not in the helix region in
Mut5 ArdA.
The concatenation of Mut5 and Mut6 to make
Mut5/6 prevented protein expression, probably
because of exacerbation of the folding problem present
in Mut5 ArdA. Leu127 and Leu134 are in contact with
each other across the dimer interface in the crystal
structure, so it was not unexpected that their replace-
ment with a large negatively charged side chain in an
already charged region (Leu127 lies within the region
mutated in Mut6 ArdA) would disrupt the interface
(L127E ArdA) and even lead to expression problems
(L134E).
Our recent mutational analysis of the Ocr DNA
mimic binding to the EcoKI MTase defined similar
regions of interactions with HsdS of EcoKI as delin-
eated here for Mut5 and Mut6 ArdA [40]. Thus,
despite the completely different folds of Ocr and
ArdA, the equivalent regions on their surface are in
contact with the EcoKI MTase. The region defined by
Mut5 ArdA interacts with part of the TRDs of HsdS,
which recognise the specified bases in the EcoKI tar-
get, i.e. the AAC and GTGC parts of the target
sequence, whereas the region defined by Mut6 ArdA
(and Leu127) interacts with the region of HsdS that
interacts nonspecifically with the six base pairs in the
middle of the bipartite target sequence. Mutations
in Ocr affecting DNA binding affinity were clustered
in the same location as Mut6 ArdA, and also resulted
Table 5. In vivo anti-RM activity of ArdA proteins. The titre of phage per millilitre was determined in E. coli NM1261(DE3, rm) and
E. coli NM1049(DE3, r+m+), and the ratio was calculated (phage per millilitre in NM1049/phage per millilitre in NM1261) to obtain the
efficiency of plating. The two strains were transformed with either the vector alone or plasmids expressing mutants of ArdA.
Plasmid name Efficiency of plating of phage k Antirestriction Antimodification Significant antimodification
ptrc99a 3.0 9 104 0.0003 0.9 –
pORF18wt 1.1 9 100 1 122.0 Yes
Mut5 6.0 9 102 0.054 0.7 No
Mut6 8.5 9 101 0.773 3.0 No
Mut5/6 3.4 9 103 0.003 0.9 No
L127E 8.6 9 101 0.782 1.0 No
L134E 2.3 9 102 0.021 3.0 No
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in a weaker interaction between the Ocr mutant and
the EcoKI MTase than between the MTase and its
DNA target.
Although the solution environment in vivo is very
different from the in vitro conditions, it appears rea-
sonable to assume that the ability to retain antirestric-
tion activity does not depend on the quaternary
structure of ArdA, as one of the monomeric forms,
L127E ArdA, retained 80% antirestriction activity,
whereas the other monomeric form, Mut5 ArdA,
showed only 5% activity. The dimeric Mut6 ArdA
retained 80% antirestriction activity. None of these
three mutants, Mut5 ArdA, Mut6 ArdA, or L127E
ArdA, showed antimodification activity in vivo.
However, if one again assumes that the in vitro results
can be extended to the in vivo situation, the inability
of these mutants to cause antimodification is not
attributable to the quaternary structure of ArdA, as
both the monomeric and dimeric mutant ArdA forms
failed to inhibit modification. Nor can the loss of anti-
modification activity be attributed to low protein
expression levels, as these mutant proteins all
expressed well. Our results obtained in vivo agree with
earlier work [21,23–25] where in vivo expression levels
of ArdA from the ColIb-P9 plasmid were varied.
These in vivo experiments showed that antirestriction
was prevalent over antimodification when the concen-
tration of ArdA was low. It was proposed that mono-
mers of ArdA inhibited only the restriction activity,
because they could only bind to the HsdRs of Type I
RM enzymes, whereas dimers of ArdA could also bind
to the MTase core of the RM enzyme [21–25]. Such
an interaction between HsdR and the Ocr antirestric-
tion protein has been observed previously [41], so it
could be expected that ArdA would also have binding
sites on the RM enzyme in addition to the binding site
on the core MTase. It would be of interest to examine
the HsdR–ArdA interactions in more detail but, unfor-
tunately, HsdR of EcoKI and the complete RM
enzyme are available in too small amounts for mean-
ingful biophysical analyses. As the structural model
suggests that domain 3 of ArdA is primarily responsi-
ble for interacting with the MTase core of the RM
enzyme (Fig. 1), domains 1 and 2 of ArdA projecting
beyond the MTase core would appear to contain the
binding surface for HsdR of the RM enzyme, as
suggested previously [18].
Finally, a search of the NCBI database using the
Tn916 ORF18 ArdA sequence and BLINK (http://
www.ncbi.nlm.nih.gov/sutils/blink.cgi?mode=query)
reveals putative ardA genes in many conjugative trans-
posons and prophage integrated into the genomes of a
large number of bacterial species. Sequenced ardA
genes are mostly predicted to encode small polypeptides
of 166–177 residues, many of which are highly acidic
and carry a net negative charge of  22 to  29. A
proportion of the putative ArdA proteins in the
NCBI database are larger than a typical ArdA, which
comprises 166–177 residues. Some of these larger ArdA
proteins contain significant N-terminal or C-terminal
extensions, indicating that the ArdA monomer has been
fused to the end of another protein. A smaller number of
putative ArdA proteins appear to have both N-terminal
and C-terminal extensions. If these sequences were
actually translated into protein, then our data on the
monomeric forms of ArdA would indicate that these
putative antirestriction proteins could bind to and inhibit
the restriction reaction of HsdRs in Type I RM systems
in a wide range of organisms.
Experimental procedures
The E. coli strains used and methods for assessing in vivo
activity of ArdA and its mutants were essentially the same
as described previously [40], although only spot tests,
rather than full plate assays, were used to determine the
antimodification activity. The protocol for analytical SEC
has been described previously [40]. The buffer for the
chromatography was 20 mM Tris, 20 mM Mes, 200 mM
NaCl, 10 mM MgCl2, 0.1 mM EDTA, and 7 mM 2-mercap-
toethanol (2-ME), adjusted to pH 6.5 with HCl. The flow
rate was set to 0.5 mL/min, and the sample volume was
40 lL. The column eluate was excited at 295 nm, and the
fluorescence emission was continuously monitored at
350 nm.
Construction of ORF18 ArdA mutants, and
protein purification and characterization
The construction of a plasmid containing the ORF18 ardA
gene from Tn916 (Fig. S1) and the purification of the pro-
tein have been described previously [17,18]. Site-directed
mutagenesis was carried out with the QuikChange II Site-
Directed Mutagenesis kit from Stratagene (La Jolla, CA,
USA), with the primers shown in Table S1, to create the
substitutions shown in Table 1. DNA sequencing confirmed
that the desired changes in the ORF18 ardA gene had been
achieved.
The ArdA proteins were overexpressed and purified as
described previously [17]. The extinction coefficient for the
monomeric form of ArdA was calculated from the amino
acid sequence (WT ORF18 ArdA, 28 020 M1cm1) and
used to calculate the protein concentration. Small differ-
ences in extinction coefficient resulting from the mutations
were ignored, as the coefficient is only accurate to  5%
[42]. All ArdA concentrations are expressed in terms of
monomer concentration.
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Equilibrium unfolding as a function of guanidinium chlo-
ride was monitored by tryptophan fluorescence spectros-
copy. WT ORF18 ArdA has two tryptophans, Trp23 and
Trp70, located in domains 1 and 2, distant from the dimer
interface. A stock solution of guanidinium chloride was
made up, and the precise concentration was determined
from the refractive index [43]. Protein (3.5 lM) in 20 mM
Tris/HCl, 10 mM MgCl2 and 7 mM 2-ME (pH 8.0) was incu-
bated with various concentrations of guanidinium chloride
at 25 °C, and allowed to equilibrate overnight. The fluores-
cence intensity was then measured for each sample, with
excitation at 295 nm and emission at 350 nm and 380 nm,
with 5-nm bandwidths, on an Edinburgh Instruments FS900
fluorimeter (Edinburgh Instruments, Livingston, UK). The
ratio of intensity at 350–380 nm was then fitted to a two-
state unfolding model assuming a linear relationship
between free energy of unfolding and the concentration of
guanidinium chloride [44]. This ratio compensates for slight
differences in the protein concentration between samples.
CD measurements were carried out on a Jasco
Model J-180 spectropolarimeter (Jasco Corporation, Tokyo,
Japan). All measurements were conducted in 20 mM sodium
phosphate, 50 mM NaF, and 0.5 mM 2-ME (pH 8.0). Far-
UV CD spectra were measured in the range 190–260 nm at
protein concentrations of 5.6–5.8 lM. All CD measurements
were made at 20 °C in a 1.0-mm pathlength cell, and each
spectrum was the average of three individual scans. The
spectra were corrected for buffer contribution.
LC-MS experiments were performed by D. Clarke
(School of Chemistry, University of Edinburgh). For
LC-MS, an Ultimate 3000 HPLC system (Dionex Corpora-
tion, Sunnyvale, CA, USA), equipped with a monolithic
PS-DVB (500 lm 9 5 mm) analytical column (Dionex
Corporation), was used. Samples containing ~ 1 lg of pro-
tein were injected into the column. MS data were acquired
on a Bruker 12 Tesla Apex Qe FT-ICR (Bruker Daltonics,
Billerica, MA, USA) equipped with an ESI source. Fast
Fourier transforms and subsequent analyses were per-
formed with DATAANALYSIS (Bruker Daltonics) software.
AUC
Prior to any AUC, the samples were analysed with UV
absorbance spectrophotometry to determine an appropriate
wavelength for data collection. Stock protein samples were
subjected to a 3000 r.p.m. ( 500 g) spin in a benchtop mi-
crocentrifuge to remove any particulates. The buffer used
was 200 mM NaCl, 20 mM Tris, 20 mM MES, and 1 mM
tris(2-carboxyethyl)phosphine (TCEP), adjusted to pH 6.5
with HCl. TCEP was used instead of 2-ME in the AUC
experiments. The density and viscosity were calculated to
be q = 1.00704 gmL1 and g = 1.026 9 102 Poise, respec-
tively. Owing to software restrictions, the values for density
and viscosity omitted the presence of 20 mM MES and
1 mM TCEP. The partial specific volumes (υ-bar) for
ORF18 ArdA and L127E ArdA were calculated from their
amino acid composition to be 0.726 mLg1 and
0.725 mLg1, respectively. The partial specific volume of
the sample and buffer density and viscosity were calculated
with SEDNTERP V1.09 (March 2006) [45].
For sedimentation equilibrium, we used samples
(0.125 mL) centrifuged in 1.2-cm pathlength six-sector epon
centrepiece cells with sapphire windows in a four-place An-
60 Ti analytical rotor at a temperature of 20 °C. Rotor
speeds (17 000, 27 000 and 35 000 r.p.m.) were calculated
on the assumption of a monomer molecular mass of
19 125 Da. Because of the range of concentrations present
(15 lM, 3 lM and 0.6 lM in monomers), radial absorbance
scans at 230, 250 and 280 nm, with 20 scans with a radial
step size of 0.001 cm, were performed and interference
scans were also performed. Scan intervals at 17 000 r.p.m.
(23 305 g) were after 12 h, and then every 1 h until equilib-
rium was reached. Scan intervals at 27 000 (58 787 g) and
35 000 r.p.m. (98 784 g) were after 9 h, and then every 1 h
until equilibrium was reached. Scans were judged to be at
equilibrium with SEDFIT V11.9 (July 2010), by looking at
the difference between successive scans [34]. Blank water
scans were also collected at all speeds and wavelengths
used. The results were analysed with SEDPHAT V6.5 (June
2009) [33] (P. Schuck, http://www.analyticalultracentrifuga-
tion.com/sedphat/sedphathtm; and https://sedfitsedphat.ni-
bib.nih.gov/default.aspx). The total run time was just over
68 h. After data collection, the rotor was accelerated to
48 000 r.p.m. (185 795 g) to pellet macromolecular material
and to measure the baseline absorbance resulting from any
low molecular mass material.
For sedimentation velocity AUC, we used 0.406-mL
samples centrifuged in 1.2-cm pathlength two-sector alu-
minium centrepiece cells built with sapphire windows in an
eight-place An50 Ti analytical rotor running in an
Optima XL-I analytical ultracentrifuge (Beckman Instru-
ments, Fullerton, CA, USA) at 50 000 r.p.m. (201 600 g)
and a temperature of 20 °C. Changes in solute concentra-
tion were detected by radial absorbance scans at 260 nm;
200 scans per cell were collected over 15 h in radial step-
wise increments of 0.003 cm, with a scan interval of 2 mins.
Results were analysed by whole boundary profile analysis
with SEDFIT V11.9 (July 2010) [34]. The fitting resolution in
SEDFIT of the sedimentation velocity AUC data is 150. The
concentration of ORF18 ArdA was 33.9 lM, and that of
L127E ArdA was 36.9 lM, in terms of monomers. Hydro-
dynamic parameters were calculated from the crystallo-
graphic data with HYDROPRO [36] and SOMO [37,38].
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